OSE Immunotherapeutics S.A.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more
OSE Immunotherapeutics S.A. (0RAD) - Total Liabilities
Latest total liabilities as of June 2021: €45.91 Million EUR
Based on the latest financial reports, OSE Immunotherapeutics S.A. (0RAD) has total liabilities worth €45.91 Million EUR as of June 2021.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OSE Immunotherapeutics S.A. - Total Liabilities Trend (2016–2020)
This chart illustrates how OSE Immunotherapeutics S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
OSE Immunotherapeutics S.A. Competitors by Total Liabilities
The table below lists competitors of OSE Immunotherapeutics S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alithya Group Inc
NASDAQ:ALYAF
|
USA | $218.38 Million |
|
Moatable Inc
NYSE:MTBLY
|
USA | $38.09 Million |
|
Woorim Machinery Co. Ltd
KQ:101170
|
Korea | ₩17.19 Billion |
|
Respiri Limited
PINK:RSHUF
|
USA | $3.55 Million |
|
1st Colonial Bancorp Inc
PINK:FCOB
|
USA | $794.48 Million |
|
TCI Express Limited
NSE:TCIEXP
|
India | ₹1.61 Billion |
|
MetaTech AP
TWO:3224
|
Taiwan | NT$942.06 Million |
|
Rhoen Klinikum AG
IL:0NQH
|
UK | €530.90 Million |
Liability Composition Analysis (2016–2020)
This chart breaks down OSE Immunotherapeutics S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OSE Immunotherapeutics S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OSE Immunotherapeutics S.A. (2016–2020)
The table below shows the annual total liabilities of OSE Immunotherapeutics S.A. from 2016 to 2020.
| Year | Total Liabilities | Change |
|---|---|---|
| 2020-12-31 | €35.61 Million | +17.15% |
| 2019-12-31 | €30.40 Million | +100.65% |
| 2018-12-31 | €15.15 Million | -30.85% |
| 2017-12-31 | €21.91 Million | -12.45% |
| 2016-12-31 | €25.02 Million | -- |